Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
Opthea Limited - American Depositary Shares (OPT)
Company Research
Source: GlobeNewswire
Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in early 2025 MELBOURNE, Australia and PRINCETON, N.J., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the completion of its drug substance Process Performance Qualification (PPQ) campaign for sozinibercept. The PPQ campaign consisted of the production of three successful consecutive commercial-scale drug substance batches required for the validation of Opthea’s manufacturing process. The batches have been produced following an extensive manufacturing process development program. “The successful completion of the drug substance PPQ campaign
Show less
Read more
Impact Snapshot
Event Time:
OPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPT alerts
High impacting Opthea Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
OPT
News
- Opthea Appoints Kathy Connell to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Opthea Appoints Kathy Connell to Board of DirectorsGlobeNewswire
- Opthea’s Wet AMD Program Featured at Ophthalmology EventsGlobeNewswire
- Age-Related Macular Degeneration (AMD) Drugs Market Research 2024: Lucentis, Eylea, Eylea HD, Vabysmo, Syfovre, Ranibizumab, Aflibercept, Faricimab, Biologic, Biosimilar - Global Forecast to 2029 [Yahoo! Finance]Yahoo! Finance
- Opthea to Participate in November Investor ConferencesGlobeNewswire
OPT
Sec Filings
- 11/19/24 - Form 6-K
- 11/15/24 - Form 6-K
- 11/14/24 - Form SC
- OPT's page on the SEC website